29May

AstraZeneca and Merck’s Lynparza (olaparib) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

AstraZeneca and Merck’s Lynparza

ASCO 2020 Virtual is happening from May 29 to May 31, and it is exciting to watch major Oncology Pharmaceutical companies and their key presentations.

AstraZeneca and Merck both the companies are worth mentioning here, as they are presenting key posters and studies on Lynparza (Olaparib) in mCRPC.

Lynparza (olaparib) Facts:
  • Lynparza (Olaparib) is the first and best in class oral poly ADP-ribose polymerase (PARP) inhibitor and the first targeted treatment to block DDR in tumors harboring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2.
  • AstraZeneca has global strategic oncology collaboration with Merck to co-develop and co-commercialize Lynparza.
  • In January 2020, the US FDA accepted the supplemental New Drug Application for Lynparza (Olaparib) and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, which have progressed following prior treatment with a new hormonal agent.
  • This product was also granted with the breakthrough designation for the monotherapy treatment of BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide) by the US FDA.
  • As per Delveinsight analysis, the combination of Lynparza (Olaparib) ± Abiraterone acetate has blockbuster potential and is expected to generate a noteworthy revenue of more than USD 1 billion in the coming years after the successful launch in the market. 
Key abstracts/Posters:
#Abstract 5538:

Impact of Olaparib vs physician’s choice of new hormonal agent (pcNHA) on the burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound

Significance: Clinical and Symptomatic patient benefit of Olaparib. 

#Abstract 5539:

Health-related quality of life (HRQoL) for Olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound

Significance: Analysis of Health-related quality of life (HRQoL) for Olaparib in metastatic castration-resistant prostate cancer (mCRPC).

#Abstract 5567:

Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Significance: Analysis of Olaparib in advanced prostate cancer pts with germline only BRCA1/2 mutations.